Mahmoud R Gaballa

7PUBLICATIONS
53CO-AUTHORS
Immunogenetics (incl. genetic immunology)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Gene and molecular therapyMolecular targetsTe urupare me te whai wāhi Māori ki te mātauranga (Māori responsiveness and engaged education)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Apr 13, 2026
Association of genetic ancestry with outcomes and toxicity of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.

Christen M Dillard, Hans Lee, Nilesh Kalariya

|Mar 28, 2026
Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium.

Andrew J Portuguese, James A Davis, Shahzad Raza

|Dec 03, 2025
Long-term outcomes and treatment patterns in Waldenström macroglobulinemia patients who discontinue Bruton tyrosine kinase inhibitor (BTKi) therapy.

Karan L Chohan, Lorenzo Gensini, Sherif Seif

|Nov 28, 2025
The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience.

Aimaz Afrough, Danai Dima, Beatrice Razzo

|Jun 25, 2025
Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium.

Danai Dima, Mariola A Vazquez-Martinez, James A Davis

|May 09, 2025
Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium.

Oren Pasvolsky, Danai Dima, Lei Feng

Pageof 2

Frequent Collaborators

7 joint publications

Krina Patel

6 joint publications

Oren Pasvolsky

4 joint publications

Andrew Portuguese

4 joint publications

James A Davis